RecruitingPremenstrual SyndromePremenstrual Dysphoric DisorderDysmenorrhea
CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life
Eligible age
18–65 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program * a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.
Sponsor: Samphire Group, Inc.
You may qualify if…
- ✓ Self-identified female, aged 18-65 years at the time of enrollment
- ✓ Basic English literacy
- ✓ Able and willing to provide informed consent electronically
- ✓ Residing in the United States
- ✓ Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)
- ✓ Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships
- ✓ Currently in full-time employment with medical benefits as part of compensation package
- ✓ Access to a smartphone with internet access compatible with the Samphire mobile application
You may not qualify if…
- ✕ Pregnancy, breastfeeding, or actively planning pregnancy during the study period
- ✕ History of epilepsy or seizure disorder
- ✕ Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation
- ✕ Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use
- ✕ Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use
- ✕ Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening
- ✕ Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening
- ✕ Inability to provide informed consent or safely use the device in the home environment
Where it's recruiting
California
San Francisco
Source: ClinicalTrials.gov · NCT07679074 · last updated 2026-07-01